Literature DB >> 19273457

Increased serum pentraxin 3 in patients with systemic sclerosis.

Yohei Iwata1, Ayumi Yoshizaki, Fumihide Ogawa, Kazuhiro Komura, Toshihide Hara, Eiji Muroi, Motoi Takenaka, Kazuhiro Shimizu, Minoru Hasegawa, Manabu Fujimoto, Kazuhiko Takehara, Shinichi Sato.   

Abstract

OBJECTIVE: To determine serum concentrations of pentraxin 3 (PTX3) and its clinical associations in patients with systemic sclerosis (SSc).
METHODS: Serum PTX3 levels from 45 patients with diffuse cutaneous SSc (dSSc), 46 with limited cutaneous SSc (lSSc), and 20 healthy controls were examined by ELISA. PTX3 expression in the sclerotic skin from SSc patients was evaluated immunohistochemically. Normal and SSc fibroblasts were cultured and PTX3 levels in the culture medium were also examined by ELISA.
RESULTS: Serum PTX3 levels were elevated in patients with SSc relative to controls. PTX3 levels in dSSc patients were significantly higher than in controls and lSSc patients. PTX3 expression in the sclerotic skin from SSc patients was more intense relative to normal skin. Elevation of serum PTX3 levels was associated with more frequent presence of pulmonary fibrosis, cardiac disease, and pitting scar/ulcer and increased serum immunoglobulin levels and erythrocyte sedimentation rates. PTX3 levels correlated positively with modified Rodnan total skin thickness score, and negatively with percentage vital capacity and percentage DLCO in patients with SSc. PTX3 levels also correlated positively with serum levels of 8-isoprostane, a marker of oxidative stress, and hyaluronan, recently identified as an endogenous ligand for Toll-like receptors. PTX3 production from cultured SSc fibroblasts was increased by stimulation with hyaluronan.
CONCLUSION: These results suggest that elevated serum PTX3 levels are associated with the disease severity of SSc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273457     DOI: 10.3899/jrheum.080343

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  15 in total

Review 1.  Application of biomarkers to clinical trials in systemic sclerosis.

Authors:  Robert Lafyatis
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

2.  Pentraxin 3 increase is much less pronounced than C-reactive protein increase after surgical procedures.

Authors:  Torbjörn Åkerfeldt; Anders Larsson
Journal:  Inflammation       Date:  2011-10       Impact factor: 4.092

3.  Low serum fibroblast growth factor 2 levels not accompanied by increased serum pentraxin 3 levels in patients with systemic sclerosis.

Authors:  Ufuk İlgen; Müçteba Enes Yayla; Nurşen Düzgün
Journal:  Clin Rheumatol       Date:  2016-11-22       Impact factor: 2.980

4.  Pentraxin 3 as a new biomarker of peritoneal injury in peritoneal dialysis patients.

Authors:  Reo Kanda; Chieko Hamada; Kayo Kaneko; Takanori Nakano; Keiichi Wakabayashi; Hiroaki Io; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  J Artif Organs       Date:  2012-09-27       Impact factor: 1.731

Review 5.  Contribution of bone marrow-derived fibrocytes to liver fibrosis.

Authors:  Jun Xu; Min Cong; Tae Jun Park; David Scholten; David A Brenner; Tatiana Kisseleva
Journal:  Hepatobiliary Surg Nutr       Date:  2015-02       Impact factor: 7.293

6.  Association study of CRP gene in systemic sclerosis in European Caucasian population.

Authors:  Julien Wipff; Philippe Dieudé; Jérôme Avouac; Eric Hachulla; Jean-Luc Cracowski; Elisabeth Diot; Luc Mouthon; Jean Sibilia; Kiet Tiev; Olivier Meyer; André Kahan; Catherine Boileau; Yannick Allanore
Journal:  Rheumatol Int       Date:  2013-02-09       Impact factor: 2.631

7.  Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease.

Authors:  Kenji Inoue; Tatsuhiko Kodama; Hiroyuki Daida
Journal:  Int J Vasc Med       Date:  2012-01-04

8.  Effect of protein kinase C delta (PKC-δ) inhibition on the transcriptome of normal and systemic sclerosis human dermal fibroblasts in vitro.

Authors:  Peter J Wermuth; Sankar Addya; Sergio A Jimenez
Journal:  PLoS One       Date:  2011-11-11       Impact factor: 3.240

9.  Prediction of a Competing Endogenous RNA Co-expression Network by Comprehensive Methods in Systemic Sclerosis-Related Interstitial Lung Disease.

Authors:  Yue-Mei Yan; Ji-Na Zheng; Li-Wei Wu; Qian-Wen Rao; Qiao-Rong Yang; Di Gao; Qiang Wang
Journal:  Front Genet       Date:  2021-07-05       Impact factor: 4.599

10.  Circulating biomarkers of interstitial lung disease in systemic sclerosis.

Authors:  Harpreet K Lota; Elisabetta A Renzoni
Journal:  Int J Rheumatol       Date:  2012-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.